MD Mednax Inc

Pacer Advisors Inc. has decreased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 21%, selling 161,982 shares and now holding 610,911 shares valued at approximately $10.23 million. Insider sales, including those by CEO Mark S. Ordan and Director Michael A. Rucker, total 43,478 shares over the last three months, bringing insider ownership to around 0.90%. Despite these sales, analysts generally maintain a "Moderate Buy" rating with a consensus price target of $21.00, following the company's strong Q3 EPS beat.

Exchange Traded Concepts LLC acquired 70,831 shares of Pediatrix Medical Group (NYSE:MD) in Q3, valued at approximately $1.19 million, increasing institutional ownership to 97.71%. Despite insider selling by two directors totaling 43,478 shares ($972,924) over three months, Pediatrix Medical Group reported strong Q3 earnings, beating analyst estimates for EPS and revenue. Several analysts have raised price targets and ratings for MD, resulting in a "Moderate Buy" average rating with a $21.00 price target.

Pediatrix Medical Group (NYSE:MD) is trading at US$21.87 with a market cap of US$1.8 billion. The company, which provides newborn, maternal-fetal, and pediatric subspecialty care services, became profitable this year and is considered to be trading below its estimated fair value. The stock has seen significant insider selling recently, but analyst consensus suggests it is undervalued with potential for growth driven by specialized pediatric and neonatal care demand and operational efficiencies.

Wedge Capital Management L L P NC has acquired a new stake of 138,228 shares (worth approximately $2.3 million) in Pediatrix Medical Group, Inc. This move increases institutional ownership to roughly 97.7%, despite recent insider selling by the CEO and a director. Pediatrix also surpassed Q3 estimates with earnings per share of $0.67 and revenues of $492.9 million, leading to a "Moderate Buy" consensus among analysts with an average price target of $21.00.

Pediatrix Medical Group (MD) has seen a significant share price rebound of 53% over the past year, prompting an assessment of its current valuation. Despite the impressive recovery, the company is still considered modestly undervalued at $21.64 against a fair value of $22.67, supported by a strong balance sheet. However, potential challenges like portfolio restructuring and rising physician compensation could impact future margin expansion.

Pediatrix Medical Group (MD) has seen a significant 53% share price rebound over the past year, currently trading at $21.64. Despite this strong performance, Simply Wall St suggests the stock is still modestly undervalued with a fair value of about $22.67, driven by improving earnings and a strong balance sheet. However, potential risks like portfolio restructuring and rising physician compensation could challenge this positive outlook.